Blood Plasma Derivatives for IVD Market
Report ID: SQMIG35J2801
Report ID: SQMIG35J2801
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35J2801 |
Region:
Global |
Published Date: August, 2026
Pages:
157
|Tables:
119
|Figures:
77
Global Blood Plasma Derivatives For Ivd Market size was valued at USD 2.31 Billion in 2024 and is poised to grow from USD 2.51 Billion in 2025 to USD 4.94 Billion by 2033, growing at a CAGR of 8.8% during the forecast period (2026-2033).
Technological advances in immunoassays and the shift toward personalized medicine drive market expansion because they require plasma derivatives with higher purity and traceability. The COVID‑19 pandemic illustrated this cause‑effect link when global serology programs needed large volumes of IgG with validated viral inactivation, prompting manufacturers to scale fractionation capacity and adopt single‑use bioreactors that lower cross‑contamination risk. Emerging economies, where healthcare spending rises, create opportunity as laboratories adopt IVD platforms that rely on plasma‑derived controls. Consequently, investment in manufacturing infrastructure and regulatory harmonization accelerates, translating into a projected double‑digit compound annual growth rate through 2032 by major diagnostic firms globally.
How is AI enhancing quality control of blood plasma derivatives in the IVD market?
AI is reshaping quality control for blood plasma derivatives by embedding deep‑learning models into imaging and spectroscopic systems. These models instantly flag anomalies in protein concentration, purity and clotting factors, reducing reliance on manual review. Real‑time data streams enable predictive maintenance of filtration equipment, cutting downtime and waste. Integration with laboratory information management systems creates a seamless feedback loop, allowing operators to adjust protocols on the fly. As the IVD sector expands, the ability to guarantee consistent plasma quality strengthens clinician confidence and supports broader adoption of plasma‑based diagnostics.
Market snapshot - (2026-2033)
Global Market Size
USD 2.31 Billion
Largest Segment
Control Plasma
Fastest Growth
Control Plasma
Growth Rate
8.8% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global blood plasma derivatives for ivd market is segmented by product type, application, end user, distribution channel and region. Based on product type, the market is segmented into Control Plasma, Calibrator Plasma, Reference Plasma and Specialty Plasma Derivatives. Based on application, the market is segmented into Coagulation Testing, Clinical Chemistry, Immunodiagnostics and Molecular Diagnostics. Based on end user, the market is segmented into Hospital Laboratories, Diagnostic Laboratories, Research Laboratories and IVD Manufacturers. Based on distribution channel, the market is segmented into Direct Sales and Distributors. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Control plasma segment dominates because it provides the essential baseline material for assay validation, ensuring consistency across manufacturers and laboratories. Its broad utility across multiple test platforms, coupled with stringent regulatory expectations for traceability, makes it indispensable. Manufacturers prioritize control plasma to mitigate variability, fostering trust among end users and reinforcing its central market position. This reliability drives repeat purchases and long‑term contracts, solidifying revenue streams for suppliers.
However, calibrator plasma segment is witnessing the strongest growth momentum because rapid assay development cycles demand precise calibration standards. Emerging multiplex platforms and digital readouts rely on these calibrators to ensure quantitative accuracy, prompting manufacturers to expand production capacities and invest in innovative formulation techniques, thereby accelerating market expansion.
Clinical chemistry segment leads because it underpins routine diagnostic panels that heavily rely on plasma-derived reagents for analyte quantification. The pervasive use in high‑throughput labs, combined with stringent quality control requirements, drives continuous demand. Its entrenched role in monitoring chronic diseases sustains steady purchasing patterns, ensuring a robust revenue base for suppliers. These dynamics encourage long‑term supplier relationships and stimulate investment in scalable manufacturing processes, reinforcing its market leadership.
On the other hand, molecular diagnostics segment is emerging as the key high‑growth area because nucleic‑acid‑based assays increasingly incorporate plasma‑derived components to boost sensitivity and specificity. The surge in personalized medicine and pathogen detection drives demand for these reagents, prompting innovators to develop tailored plasma fractions, which expands market opportunities and attracts new entrants.
To get detailed segments analysis, Request a Free Sample Report
North America sustains its leadership in the blood plasma derivatives for IVD market through a convergence of advanced research infrastructure, robust regulatory frameworks, and a mature healthcare ecosystem that prioritizes diagnostic excellence. The region benefits from deep expertise in plasma processing technologies and a high concentration of specialized manufacturers that drive continuous product innovation. Strong collaboration among academic institutions, biotech firms, and clinical laboratories fuels rapid translation of scientific breakthroughs into commercial offerings. Additionally, extensive reimbursement mechanisms and well‑established supply chains ensure reliable access to high‑quality plasma‑derived reagents, reinforcing market stability and reinforcing North America’s dominant position. The region also attracts significant foreign investment, encouraging cross‑border partnerships that further enhance technological capabilities and expand global reach of North American plasma derivative solutions.
Blood Plasma Derivatives for IVD Market in the United States is propelled by a dense network of leading biotech firms and research universities that focus on plasma fractionation and diagnostic reagent development. The regulatory environment offers clear pathways for product approval, encouraging innovation while ensuring safety. Strong collaboration between clinical labs and manufacturers accelerates feedback loops, refining assay performance and driving adoption across diverse healthcare settings throughout the nation broadly.
Blood Plasma Derivatives for IVD Market in Canada benefits from a supportive public‑health framework that emphasizes early adoption of advanced diagnostic tools. Collaborative initiatives between provincial health authorities and plasma processing companies foster localized development of high‑quality reagents. The presence of world‑class research institutions contributes to a pipeline of innovative technologies, while a focus on cost‑effective solutions drives integration of plasma derivatives across both urban and remote clinical environments nationwide.
Europe experiences rapid expansion of the blood plasma derivatives for IVD market due to a synergistic blend of strong scientific research ecosystems, well‑established clinical networks, and harmonized regulatory standards across the region. Investment in precision medicine drives demand for highly specific plasma‑derived reagents, while collaborative platforms linking universities, biotech incubators, and diagnostic manufacturers accelerate innovation cycles. Patient‑centric healthcare policies prioritize early detection, creating a fertile environment for adoption of advanced IVD solutions. Moreover, cross‑border trade agreements and shared quality frameworks facilitate seamless distribution, enhancing market accessibility and fostering a cohesive European leadership in plasma‑based diagnostics. The region’s commitment to sustainability also encourages the development of environmentally responsible plasma processing methods, which resonates with manufacturers seeking greener production pathways and further reinforces Europe’s competitive advantage in the global diagnostic landscape.
Blood Plasma Derivatives for IVD Market in Germany is anchored by a robust network of research institutes and a strong pharmaceutical base that emphasizes high‑quality plasma processing. The national regulatory authority provides clear guidance that streamlines product development, while public funding programs support translational projects. Close collaboration between hospitals and biotech firms ensures that clinical requirements shape reagent design, leading to widespread adoption across the country’s advanced diagnostic laboratories nationwide.
Blood Plasma Derivatives for IVD Market in the United Kingdom is propelled by a biotech sector and academic hospitals that drive translation of plasma‑based diagnostics. The regulatory environment balances thorough assessment with flexibility, encouraging innovative assay development. Initiatives aimed at health technology adoption accelerate market entry, while collaborations between research councils and firms nurture a pipeline of novel plasma reagents. This ecosystem supports implementation across health services and laboratory networks.
Blood Plasma Derivatives for IVD Market in France is emerging through investment in biotechnology clusters and commitment to precision diagnostics. Collaborative programs between research institutes and plasma processing companies encourage development of tailored reagents for clinical applications. The French regulatory framework provides a pathway for approvals, facilitating market entry for innovative products. Growing awareness of disease detection among clinicians further drives adoption of plasma‑based IVD solutions across hospitals and laboratories.
Asia Pacific is strengthening its position in the blood plasma derivatives for IVD market by leveraging rapid advancements in biotechnology, expanding healthcare infrastructure, and increasing emphasis on early diagnostic capabilities across the region. Strategic investments by governments and private partners support the establishment of state‑of‑the‑art plasma processing facilities, enabling greater self‑sufficiency and reduced reliance on imports. Collaborative research programs linking universities with emerging biotech firms accelerate the development of innovative plasma‑derived reagents tailored to regional disease profiles. Moreover, growing awareness of preventive health drives demand for high‑precision IVD solutions, prompting manufacturers to prioritize market entry strategies that address local regulatory requirements and cultural considerations. This multifaceted approach positions Asia Pacific as a competitive hub for plasma‑based diagnostic technologies in the near future.
Blood Plasma Derivatives for IVD Market in Japan benefit from a mature diagnostic industry and strong governmental support for biopharmaceutical innovation. Leading research universities collaborate closely with plasma processing firms to create high‑purity reagents suited for the nation’s clinical testing network. Clear regulatory pathways streamline product certification, while a culture of precision medicine accelerates adoption across hospitals and specialized laboratories, establishing Japan as a key hub for plasma‑based diagnostic solutions.
Blood Plasma Derivatives for IVD Market in South Korea are propelled by government initiatives aimed at advancing biotech capabilities and enhancing health surveillance. Partnerships between major hospitals and plasma technology firms foster rapid prototyping of reagents that address regional diseases. Streamlined regulatory processes reduce time to market, while incentives for local manufacturing encourage domestic production. This supportive ecosystem accelerates integration of plasma‑derived diagnostics into routine clinical practice throughout the country.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Demand for Diagnostic Tests
Advancements in Plasma Processing Technologies
Stringent Regulatory Approval Processes
Limited Donor Supply and Collection
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape is shaped by established plasma specialists leveraging strategic M&A and partnership deals to expand their IVD portfolios, while emerging players accelerate growth through technology‑focused collaborations and targeted funding rounds; Grifols, for example, has pursued acquisitions of niche plasma product firms to broaden its diagnostic offering, and recent joint ventures with regional biotech firms aim to accelerate market entry in high‑growth Asia‑Pacific markets.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global blood plasma derivatives market is propelled foremost by the rising demand for diagnostic tests as chronic diseases increase and clinicians seek more accurate biomarkers, while rapid advances in plasma processing technologies boost yields and safety, further accelerating growth. The control plasma segment remains the market’s backbone because it provides essential baseline material for assay validation across multiple platforms. North America leads the landscape thanks to its advanced research infrastructure, robust regulatory framework, and extensive reimbursement networks. However, the stringent regulatory approval processes pose a notable restraint, extending development timelines and raising costs for manufacturers seeking entry worldwide.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 2.31 Billion |
| Market size value in 2033 | USD 4.94 Billion |
| Growth Rate | 8.8% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Blood Plasma Derivatives for IVD Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Blood Plasma Derivatives for IVD Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Blood Plasma Derivatives for IVD Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Blood Plasma Derivatives for IVD Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Blood Plasma Derivatives For Ivd Market size was valued at USD 2.31 Billion in 2024 and is poised to grow from USD 2.51 Billion in 2025 to USD 4.94 Billion by 2033, growing at a CAGR of 8.8% during the forecast period (2026-2033).
The competitive landscape is shaped by established plasma specialists leveraging strategic M&A and partnership deals to expand their IVD portfolios, while emerging players accelerate growth through technology‑focused collaborations and targeted funding rounds; Grifols, for example, has pursued acquisitions of niche plasma product firms to broaden its diagnostic offering, and recent joint ventures with regional biotech firms aim to accelerate market entry in high‑growth Asia‑Pacific markets. 'Siemens Healthineers AG', 'F. Hoffmann-La Roche Ltd.', 'Abbott Laboratories', 'Danaher Corporation', 'Thermo Fisher Scientific Inc.', 'Bio-Rad Laboratories, Inc.', 'bioMérieux SA', 'DiaSorin S.p.A.', 'Werfen, S.A.', 'Grifols, S.A.', 'QuidelOrtho Corporation', 'Sysmex Corporation', 'Sekisui Medical Co., Ltd.', 'Trinity Biotech plc', 'Randox Laboratories Ltd.', 'Agilent Technologies, Inc.', 'Merck KGaA', 'PerkinElmer, Inc.', 'Becton, Dickinson and Company', 'Gold Standard Diagnostics Corporation'
Rising prevalence of chronic diseases and heightened awareness of early detection drive hospitals and laboratories to adopt sophisticated in‑vitro diagnostic assays, which rely heavily on high‑quality plasma derivatives. As clinicians seek more accurate biomarkers, the need for reliable reagents expands, prompting manufacturers to scale production and invest in distribution networks. This growing clinical reliance fosters sustained demand for plasma‑based diagnostics, encouraging new product introductions and supporting overall market expansion across regional healthcare systems and strengthens partnerships between suppliers and clinical research organizations.
Personalized Therapeutics Expansion: Healthcare providers increasingly prioritize customized plasma-derived solutions, driven by advances in diagnostic precision and patient stratification. This shift encourages manufacturers to diversify their product portfolios, integrating recombinant technologies and tailored formulations that address specific disease phenotypes. Collaborative research networks accelerate knowledge sharing, while clinicians seek evidence of superior outcomes. Consequently, market participants invest in flexible manufacturing platforms and adaptive regulatory pathways, positioning themselves to meet evolving clinical demands and capture premium pricing for niche therapeutic offerings across global healthcare ecosystems.
Why does North America Dominate the Global Blood Plasma Derivatives for IVD Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
